ACE Inhibitors

  • Pedro D’Orléans-Juste
  • Gérard E. Plante

Part of the Milestones in Drug Therapy MDT book series (MDT)

Table of contents

  1. Front Matter
    Pages I-X
  2. Paulus Wohlfart, Gabriele Wiemer, Wolfgang Linz, Bernward A. Schölkens
    Pages 29-36
  3. Rob L. Hopfner, J. Robert McNeill, Venkat Gopalakrishnan
    Pages 37-45
  4. Maxime Lamarre-Cliche, Pierre Larochelle
    Pages 47-70
  5. Irene Gavras, Haralambos Gavras
    Pages 71-79
  6. Gérard E. Plante, Tewfik Nawar
    Pages 81-103
  7. Michel E. Safar, Harry A. J. Struijker Boudier, Luc M. A. B. Van Bortel, Gérard M. London
    Pages 105-127
  8. Jacques de Champlain, Pedro D’Orléans-Juste
    Pages 145-153
  9. Stylianos E. Orfanos, Linhua Zou, John D. Catravas
    Pages 163-170
  10. Tewfik Nawar, Eve-Reine Gagné, Raymonde Turcotte, Gérard E. Plante
    Pages 171-176
  11. Mark E. Cooper
    Pages 177-184
  12. Back Matter
    Pages 185-187

About this book


Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis­ order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun­ tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop­ ment almost failed when serious side-effects were reported in an alarmist fash­ ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar­ macological actions.


diseases enzymes genetics health policy heart metabolism nervous system pharmacodynamics research therapy tissue

Editors and affiliations

  • Pedro D’Orléans-Juste
    • 1
  • Gérard E. Plante
    • 1
    • 2
  1. 1.Department of Pharmacology, Institute of Pharmacology of Sherbrooke, Medical SchoolSherbrooke UniversitySherbrookeCanada
  2. 2.Departments of Medicine (Nephrology), Physiology and Pharmacology, Institute of PharmacologyUniversity of SherbrookeSherbrookeCanada

Bibliographic information